11:34 AM EST - VBI Vaccines Inc. : Has completed a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration to discuss the Phase III clinical program for Sci-B-Vac™, VBI's third-generation hepatitis B vaccine. Sci-B-Vac™ is currently approved for use in Israel and 14 other countries worldwide. VBI Vaccines Inc.
shares T.VBV are trading down $0.28 at $5.71.
